We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has issued a public health warning about the potential cancer risks
of two eczema drugs -- Novartis Pharmaceutical's Elidel and Fujisawa Healthcare's
Protopic.
OncoGenex Technologies and Isis Pharmaceuticals announced they have broadened
their antisense drug development partnership to allow for the development of
two additional second-generation antisense anticancer drug candidates.
Cyclacel Group, the cell cycle-based biopharmaceutical company, announced execution
of a research collaboration agreement with ALTANA Pharma AG, the pharmaceutical
division of ALTANA AG, in which Cyclacel will use its expertise in mitosis or
cell division to identify the molecular targets of specific ALTANA Pharma experimental
drugs.
Novavax, a specialty biopharmaceutical company, and Ranbaxy Laboratories, have
entered into an agreement to evaluate a new transdermal product (this is a new
product and is not related to ESTRASORB).
Predix Pharmaceuticals Holdings Inc., a drug discovery and development company,
and Cystic Fibrosis Foundation Therapeutics (CFFT), the drug discovery and development
affiliate of the Cystic Fibrosis Foundation, announced that they have signed
a research, development and commercialization agreement.
KaloBios Pharmaceuticals, a privately-held emerging therapeutic antibody company,
announced the completion of its Series B financing round of $20 million.
Geneva Pharmaceuticals, which changed its name to Sandoz in 2003, and Abbott
Laboratories have settled a lawsuit with the attorneys general of Colorado,
Florida and Kansas, the Colorado Attorney General's office said Monday.
Sigma-Aldrich Corp. will serve as a scientific collaborator
and distribution partner of the RNAi Consortium under an agreement with the
Massachusetts Institute of Technology.
Former HHS Secretary Tommy Thompson has accepted two positions in the private
sector - one with law firm Akin Gump Strauss and another with consulting firm
Deloitte & Touche, the companies recently announced.